Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developability.
Fab
Fv
IgG1
IgG4P
aggregation
antibody
isotype
mAb
prediction
Journal
Protein engineering, design & selection : PEDS
ISSN: 1741-0134
Titre abrégé: Protein Eng Des Sel
Pays: England
ID NLM: 101186484
Informations de publication
Date de publication:
31 12 2019
31 12 2019
Historique:
received:
22
07
2019
revised:
17
10
2019
accepted:
19
11
2019
pubmed:
24
12
2019
medline:
15
7
2020
entrez:
24
12
2019
Statut:
ppublish
Résumé
Native state aggregation is an important concern in the development of therapeutic antibodies. Enhanced knowledge of mAb native state aggregation mechanisms would permit sequence-based selection and design of therapeutic mAbs with improved developability. We investigated how electrostatic interactions affect the native state aggregation of seven human IgG1 and IgG4P mAb isotype pairs, each pair having identical variable domains that are different for each set of IgG1 and IgG4P constructs. Relative aggregation propensities were determined at pH 7.4, representing physiological conditions, and pH 5.0, representing commonly used storage conditions. Our work indicates that the net charge state of variable domains relative to the net charge state of the constant domains is predominantly responsible for the different native state aggregation behavior of IgG1 and IgG4P mAbs. This observation suggests that the global net charge of a multi domain protein is not a reliable predictor of aggregation propensity. Furthermore, we demonstrate a design strategy in the frameworks of variable domains to reduce the native state aggregation propensity of mAbs identified as being aggregation-prone. Importantly, substitution of specifically identified residues with alternative, human germline residues, to optimize Fv charge, resulted in decreased aggregation potential at pH 5.0 and 7.4, thus increasing developability.
Identifiants
pubmed: 31868219
pii: 5685394
doi: 10.1093/protein/gzz046
pmc: PMC7036597
doi:
Substances chimiques
Immunoglobulin G
0
Protein Aggregates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-288Informations de copyright
© The Author(s) 2019. Published by Oxford University Press.
Références
Mol Immunol. 1993 Jan;30(1):105-8
pubmed: 8417368
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Mol Biol. 2017 Apr 21;429(8):1244-1261
pubmed: 28322916
MAbs. 2016 Nov/Dec;8(8):1561-1574
pubmed: 27560842
Patient Prefer Adherence. 2015 Jul 02;9:923-42
pubmed: 26170642
J Pharm Sci. 2016 Aug;105(8):2319-27
pubmed: 27368120
J Pharm Sci. 2014 Jan;103(1):115-27
pubmed: 24282022
J Control Release. 2014 May 28;182:22-32
pubmed: 24631859
J Phys Chem B. 2012 Jul 19;116(28):8045-57
pubmed: 22694284
MAbs. 2019 Feb/Mar;11(2):388-400
pubmed: 30523762
J Pharm Sci. 2016 Feb;105(2):417-430
pubmed: 26869409
Biotechnol Prog. 2010 May-Jun;26(3):697-705
pubmed: 20014099
J Pharm Sci. 2018 May;107(5):1247-1260
pubmed: 29336981
J Pharm Sci. 2007 Jan;96(1):1-26
pubmed: 16998873
J Pharm Sci. 2011 Mar;100(3):1009-21
pubmed: 21280052
Drug Metab Dispos. 2014 Nov;42(11):1881-9
pubmed: 25100673
Protein Sci. 2013 Aug;22(8):1118-23
pubmed: 23740802
Protein Sci. 2012 Sep;21(9):1315-22
pubmed: 22761163
MAbs. 2010 Sep-Oct;2(5):480-99
pubmed: 20647768
MAbs. 2019 May/Jun;11(4):747-756
pubmed: 30913963
Proteins. 1996 May;25(1):130-3
pubmed: 8727325
J Mol Biol. 2009 Aug 14;391(2):404-13
pubmed: 19527731
J Pharm Sci. 2012 Jan;101(1):102-15
pubmed: 21935950
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
Nat Rev Drug Discov. 2004 Aug;3(8):711-5
pubmed: 15286737
Trends Biotechnol. 2019 Mar;37(3):237-241
pubmed: 30316558
Malar J. 2008 Jul 14;7:129
pubmed: 18625058
J Biol Chem. 1981 Dec 10;256(23):12108-17
pubmed: 7298647
Protein Sci. 2010 May;19(5):954-66
pubmed: 20198683
J Biol Chem. 2012 Jul 13;287(29):24525-33
pubmed: 22610095
N Engl J Med. 2003 Feb 13;348(7):601-8
pubmed: 12584368
Protein Eng Des Sel. 2012 Oct;25(10):531-7
pubmed: 22915597
Int J Pharm. 2018 Oct 25;550(1-2):251-268
pubmed: 30145245
J Biomol Screen. 2015 Apr;20(4):468-83
pubmed: 25576149
J Pharm Sci. 2015 Jun;104(6):1885-1898
pubmed: 25821140
J Pharm Sci. 2004 Jun;93(6):1390-402
pubmed: 15124199
J Pharm Sci. 2011 Feb;100(2):354-87
pubmed: 20740683
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
J Mol Recognit. 2012 Mar;25(3):165-73
pubmed: 22407980
Methods Enzymol. 1990;182:301-6
pubmed: 2314243
Sci Rep. 2016 Dec 20;6:38644
pubmed: 27995962
Biotechnol Bioeng. 1998 May 20;58(4):451
pubmed: 10099280
World J Biol Chem. 2012 Apr 26;3(4):73-92
pubmed: 22558487
AAPS J. 2006 Sep 15;8(3):E572-9
pubmed: 17025275
J Mol Biol. 2017 Feb 3;429(3):356-364
pubmed: 27561707
BioDrugs. 2016 Jun;30(3):195-206
pubmed: 27097915
Protein Eng Des Sel. 2010 Aug;23(8):643-51
pubmed: 20543007
Biochim Biophys Acta. 1964 Mar 16;82:463-75
pubmed: 14148814
Curr Opin Biotechnol. 2009 Dec;20(6):708-14
pubmed: 19880308